Benzinga | Jul 16, 2020 08:10AM EDT

Leading Independent Proxy Advisory Firms ISS And Glass Lewis Both Support Biocept Proposal To Authorize Reverse Split Of Common Shares

SAN DIEGO, July 16, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis) both have recommended that stockholders vote in favor of Biocept's proxy proposal to authorize a reverse stock split of Biocept's common stock, as further described in Biocept's Proxy Statement for its 2020 Annual Meeting of Stockholders. This item is Proposal 4 on the Biocept's proxy card (the "Proposal").